C

Clinical Research Center of the Carolinas | Charleston, SC

Research site
(Unclaimed)
Location
1364 Ashley River Road, Charleston, South Carolina, United States of America
Site insights

Top conditions

Psoriasis (12 trials)

Atopic Dermatitis (9 trials)

Dermatitis (9 trials)

Eczema (8 trials)

Basal Cell Carcinoma (4 trials)

Top treatments

Deucravacitinib
CTP-543
cemiplimab
BMS-986165
BI 730357
Ruxolitinib
Sofpironium Bromide
Amlitelimab
KX2-391
JTE-051

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

12 of 39
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Enrolling
Plaque Psoriasis
Drug: TAK-279
Drug: Apremilast

The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and ge...

Enrolling
Palmoplantar Psoriasis
Genital Psoriasis
Drug: Deucravacitinib
Drug: Placebo

The purpose of this study is to assess the safety, efficacy, and tolerability of deucravacitinib (BMS-986165) compared with placebo in participants w...

Enrolling
Lupus Erythematosus, Subacute Cutaneous
Lupus Erythematosus, Discoid
Drug: Deucravacitinib
Drug: Placebo

The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community...

Enrolling
Psoriasis
Other: Placebo
Drug: Deucravacitinib

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participant...

Enrolling
Dermatitis Atopic
Drug: Amlitelimab
Drug: Topical corticosteroids

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Invitation-only
Alopecia Areata
Drug: CTP-543

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have bee...

Active, not recruiting
Psoriasis
Drug: BMS-986165

The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-Rhod...

Enrolling
Acne Vulgaris
Combination Product: 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product: 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)

The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) with the medication Ameluz® performed with the PDT-lamp BF-Rho...

Active, not recruiting
Superficial Basal Cell Carcinoma
Combination Product: Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product: Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)

The aim of this study is to test the safety. tolerability and efficacy of field-directed photodynamic therapy (PDT) with 10% aminolevulinic acid gel...

Enrolling
Actinic Keratoses
Combination Product: BF-200 ALA and red light LED lamp
Combination Product: Vehicle and red light LED lamp

The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.

Enrolling
Atopic Dermatitis
Drug: ruxolitinib cream

Trial sponsors

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS) (5 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems